IL94749A - Sustained-release film-forming liquid acrylic polymer pharmaceutical composition - Google Patents

Sustained-release film-forming liquid acrylic polymer pharmaceutical composition

Info

Publication number: IL94749A
Authority: IL; Israel
Prior art keywords: liquid polymer; release; agent; polymer composition; group
Prior art date: 1989-06-21

Application number

IL9474990A

Other languages

English (en)

Original Assignee

Yissum Res Dev Co

Perio Prod Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1989-06-21

Filing date

1990-06-15

Publication date

1995-01-24

1989-06-21 Priority claimed from US07/369,223 external-priority patent/US5330746A/en

1990-06-15 Application filed by Yissum Res Dev Co, Perio Prod Ltd filed Critical Yissum Res Dev Co

1995-01-24 Publication of IL94749A publication Critical patent/IL94749A/en

Links

239000007788 liquid Substances 0.000 title claims abstract description 151
239000012730 sustained-release form Substances 0.000 title claims abstract description 42
238000013268 sustained release Methods 0.000 title claims abstract description 39
229920000058 polyacrylate Polymers 0.000 title claims description 20
239000008194 pharmaceutical composition Substances 0.000 title description 2
239000000203 mixture Substances 0.000 claims abstract description 308
239000003795 chemical substances by application Substances 0.000 claims abstract description 72
239000002831 pharmacologic agent Substances 0.000 claims abstract description 21
229920000642 polymer Polymers 0.000 claims description 202
YMKDRGPMQRFJGP-UHFFFAOYSA-M cetylpyridinium chloride Chemical compound [Cl-].CCCCCCCCCCCCCCCC[N+]1=CC=CC=C1 YMKDRGPMQRFJGP-UHFFFAOYSA-M 0.000 claims description 81
229960001927 cetylpyridinium chloride Drugs 0.000 claims description 81
VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 claims description 78
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 53
206010020751 Hypersensitivity Diseases 0.000 claims description 40
208000026935 allergic disease Diseases 0.000 claims description 34
229920001223 polyethylene glycol Polymers 0.000 claims description 33
239000002202 Polyethylene glycol Substances 0.000 claims description 32
230000009610 hypersensitivity Effects 0.000 claims description 32
239000003429 antifungal agent Substances 0.000 claims description 31
239000004472 Lysine Substances 0.000 claims description 30
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims description 30
KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 30
229940121375 antifungal agent Drugs 0.000 claims description 27
239000003242 anti bacterial agent Substances 0.000 claims description 24
235000019441 ethanol Nutrition 0.000 claims description 24
239000001509 sodium citrate Substances 0.000 claims description 24
229920001577 copolymer Polymers 0.000 claims description 22
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
239000004014 plasticizer Substances 0.000 claims description 15
CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 claims description 13
229910001631 strontium chloride Inorganic materials 0.000 claims description 12
AHBGXTDRMVNFER-UHFFFAOYSA-L strontium dichloride Chemical compound [Cl-].[Cl-].[Sr+2] AHBGXTDRMVNFER-UHFFFAOYSA-L 0.000 claims description 12
NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 claims description 11
WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 claims description 10
DOIRQSBPFJWKBE-UHFFFAOYSA-N dibutyl phthalate Chemical compound CCCCOC(=O)C1=CC=CC=C1C(=O)OCCCC DOIRQSBPFJWKBE-UHFFFAOYSA-N 0.000 claims description 10
230000002421 anti-septic effect Effects 0.000 claims description 8
125000001453 quaternary ammonium group Chemical group 0.000 claims description 8
150000003242 quaternary ammonium salts Chemical class 0.000 claims description 8
230000003115 biocidal effect Effects 0.000 claims description 7
KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims description 6
QGZKDVFQNNGYKY-UHFFFAOYSA-O ammonium group Chemical group [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 claims description 6
239000003443 antiviral agent Substances 0.000 claims description 6
125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
150000004676 glycans Chemical class 0.000 claims description 6
150000002632 lipids Chemical class 0.000 claims description 6
229920001282 polysaccharide Polymers 0.000 claims description 6
239000005017 polysaccharide Substances 0.000 claims description 6
APSBXTVYXVQYAB-UHFFFAOYSA-M sodium docusate Chemical compound [Na+].CCCCC(CC)COC(=O)CC(S([O-])(=O)=O)C(=O)OCC(CC)CCCC APSBXTVYXVQYAB-UHFFFAOYSA-M 0.000 claims description 6
239000004475 Arginine Substances 0.000 claims description 5
NIXOWILDQLNWCW-UHFFFAOYSA-N acrylic acid group Chemical group C(C=C)(=O)O NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 claims description 5
235000001014 amino acid Nutrition 0.000 claims description 5
150000001413 amino acids Chemical class 0.000 claims description 5
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 claims description 5
229960000686 benzalkonium chloride Drugs 0.000 claims description 5
239000003431 cross linking reagent Substances 0.000 claims description 5
125000005397 methacrylic acid ester group Chemical group 0.000 claims description 5
239000001103 potassium chloride Substances 0.000 claims description 5
235000011164 potassium chloride Nutrition 0.000 claims description 5
FGIUAXJPYTZDNR-UHFFFAOYSA-N potassium nitrate Chemical compound [K+].[O-][N+]([O-])=O FGIUAXJPYTZDNR-UHFFFAOYSA-N 0.000 claims description 5
235000018102 proteins Nutrition 0.000 claims description 5
102000004169 proteins and genes Human genes 0.000 claims description 5
108090000623 proteins and genes Proteins 0.000 claims description 5
159000000008 strontium salts Chemical class 0.000 claims description 5
QGAPCDHPGCYAKM-UHFFFAOYSA-H tristrontium;2-hydroxypropane-1,2,3-tricarboxylate Chemical compound [Sr+2].[Sr+2].[Sr+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QGAPCDHPGCYAKM-UHFFFAOYSA-H 0.000 claims description 5
RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 claims description 4
CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 4
KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 claims description 4
JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims description 4
235000003704 aspartic acid Nutrition 0.000 claims description 4
OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 claims description 4
239000002253 acid Substances 0.000 claims description 3
235000016337 monopotassium tartrate Nutrition 0.000 claims description 3
XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 claims description 3
KYKNRZGSIGMXFH-ZVGUSBNCSA-M potassium bitartrate Chemical compound [K+].OC(=O)[C@H](O)[C@@H](O)C([O-])=O KYKNRZGSIGMXFH-ZVGUSBNCSA-M 0.000 claims description 3
229940086065 potassium hydrogentartrate Drugs 0.000 claims description 3
235000019830 sodium polyphosphate Nutrition 0.000 claims description 3
ANOBYBYXJXCGBS-UHFFFAOYSA-L stannous fluoride Chemical group F[Sn]F ANOBYBYXJXCGBS-UHFFFAOYSA-L 0.000 claims description 3
229960002799 stannous fluoride Drugs 0.000 claims description 3
229920002307 Dextran Polymers 0.000 claims description 2
SXRSQZLOMIGNAQ-UHFFFAOYSA-N Glutaraldehyde Chemical compound O=CCCCC=O SXRSQZLOMIGNAQ-UHFFFAOYSA-N 0.000 claims description 2
239000004323 potassium nitrate Substances 0.000 claims description 2
235000010333 potassium nitrate Nutrition 0.000 claims description 2
125000004185 ester group Chemical group 0.000 claims 4
229940102838 methylmethacrylate Drugs 0.000 claims 4
230000007935 neutral effect Effects 0.000 claims 4
DPBJAVGHACCNRL-UHFFFAOYSA-N 2-(dimethylamino)ethyl prop-2-enoate Chemical compound CN(C)CCOC(=O)C=C DPBJAVGHACCNRL-UHFFFAOYSA-N 0.000 claims 2
MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims 2
XIWFQDBQMCDYJT-UHFFFAOYSA-M benzyl-dimethyl-tridecylazanium;chloride Chemical compound [Cl-].CCCCCCCCCCCCC[N+](C)(C)CC1=CC=CC=C1 XIWFQDBQMCDYJT-UHFFFAOYSA-M 0.000 claims 2
SUPCQIBBMFXVTL-UHFFFAOYSA-N ethyl 2-methylprop-2-enoate Chemical compound CCOC(=O)C(C)=C SUPCQIBBMFXVTL-UHFFFAOYSA-N 0.000 claims 2
229940063557 methacrylate Drugs 0.000 claims 2
ODKSFYDXXFIFQN-BYPYZUCNSA-P L-argininium(2+) Chemical compound NC(=[NH2+])NCCC[C@H]([NH3+])C(O)=O ODKSFYDXXFIFQN-BYPYZUCNSA-P 0.000 claims 1
JMTCDHVHZSGGJA-UHFFFAOYSA-M potassium hydrogenoxalate Chemical group [K+].OC(=O)C([O-])=O JMTCDHVHZSGGJA-UHFFFAOYSA-M 0.000 claims 1
238000011282 treatment Methods 0.000 abstract description 54
238000001035 drying Methods 0.000 abstract description 29
230000002265 prevention Effects 0.000 abstract description 23
229920003145 methacrylic acid copolymer Polymers 0.000 abstract description 11
239000007787 solid Substances 0.000 abstract description 2
238000009472 formulation Methods 0.000 description 85
229920003134 Eudragit® polymer Polymers 0.000 description 76
210000000515 tooth Anatomy 0.000 description 55
229910052712 strontium Inorganic materials 0.000 description 45
CIOAGBVUUVVLOB-UHFFFAOYSA-N strontium atom Chemical compound [Sr] CIOAGBVUUVVLOB-UHFFFAOYSA-N 0.000 description 45
239000003814 drug Substances 0.000 description 44
229940079593 drug Drugs 0.000 description 42
229920002565 Polyethylene Glycol 400 Polymers 0.000 description 38
238000000034 method Methods 0.000 description 35
230000001186 cumulative effect Effects 0.000 description 34
230000000694 effects Effects 0.000 description 34
239000002250 absorbent Substances 0.000 description 33
230000002745 absorbent Effects 0.000 description 33
210000000214 mouth Anatomy 0.000 description 30
229960003646 lysine Drugs 0.000 description 28
235000018977 lysine Nutrition 0.000 description 28
208000015181 infectious disease Diseases 0.000 description 27
WXNZTHHGJRFXKQ-UHFFFAOYSA-N 4-chlorophenol Chemical compound OC1=CC=C(Cl)C=C1 WXNZTHHGJRFXKQ-UHFFFAOYSA-N 0.000 description 24
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 24
238000000338 in vitro Methods 0.000 description 23
201000010099 disease Diseases 0.000 description 21
210000001519 tissue Anatomy 0.000 description 20
210000004262 dental pulp cavity Anatomy 0.000 description 18
230000015556 catabolic process Effects 0.000 description 16
238000006731 degradation reaction Methods 0.000 description 16
230000001965 increasing effect Effects 0.000 description 16
239000000243 solution Substances 0.000 description 15
HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 15
229940038773 trisodium citrate Drugs 0.000 description 15
239000013543 active substance Substances 0.000 description 14
230000000844 anti-bacterial effect Effects 0.000 description 14
208000028169 periodontal disease Diseases 0.000 description 14
241001465754 Metazoa Species 0.000 description 13
230000002882 anti-plaque Effects 0.000 description 13
230000007774 longterm Effects 0.000 description 13
ISPYQTSUDJAMAB-UHFFFAOYSA-N 2-chlorophenol Chemical compound OC1=CC=CC=C1Cl ISPYQTSUDJAMAB-UHFFFAOYSA-N 0.000 description 12
239000001856 Ethyl cellulose Substances 0.000 description 12
ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 12
208000002925 dental caries Diseases 0.000 description 12
229920001249 ethyl cellulose Polymers 0.000 description 12
235000019325 ethyl cellulose Nutrition 0.000 description 12
238000002474 experimental method Methods 0.000 description 12
238000002360 preparation method Methods 0.000 description 12
-1 stannous fluoride) Chemical compound 0.000 description 12
KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 11
201000003984 candidiasis Diseases 0.000 description 11
229940013553 strontium chloride Drugs 0.000 description 11
UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 10
241000222122 Candida albicans Species 0.000 description 10
206010007134 Candida infections Diseases 0.000 description 10
208000031888 Mycoses Diseases 0.000 description 10
239000001110 calcium chloride Substances 0.000 description 10
229910001628 calcium chloride Inorganic materials 0.000 description 10
235000011148 calcium chloride Nutrition 0.000 description 10
229940117841 methacrylic acid copolymer Drugs 0.000 description 10
230000002035 prolonged effect Effects 0.000 description 10
230000000699 topical effect Effects 0.000 description 10
GMDACCYEPJRFLD-UHFFFAOYSA-N 4-chlorophenol;4,7,7-trimethylbicyclo[2.2.1]heptan-3-one Chemical compound OC1=CC=C(Cl)C=C1.C1CC2(C)C(=O)CC1C2(C)C GMDACCYEPJRFLD-UHFFFAOYSA-N 0.000 description 9
208000007027 Oral Candidiasis Diseases 0.000 description 9
239000000654 additive Substances 0.000 description 9
230000003902 lesion Effects 0.000 description 9
239000011159 matrix material Substances 0.000 description 9
229960000988 nystatin Drugs 0.000 description 9
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 description 9
230000001954 sterilising effect Effects 0.000 description 9
238000004659 sterilization and disinfection Methods 0.000 description 9
208000006819 Denture Stomatitis Diseases 0.000 description 8
206010017533 Fungal infection Diseases 0.000 description 8
206010028980 Neoplasm Diseases 0.000 description 8
230000001580 bacterial effect Effects 0.000 description 8
239000000872 buffer Substances 0.000 description 8
239000007853 buffer solution Substances 0.000 description 8
239000002324 mouth wash Substances 0.000 description 8
235000002639 sodium chloride Nutrition 0.000 description 8
238000002560 therapeutic procedure Methods 0.000 description 8
241000222120 Candida <Saccharomycetales> Species 0.000 description 7
GHXZTYHSJHQHIJ-UHFFFAOYSA-N Chlorhexidine Chemical compound C=1C=C(Cl)C=CC=1NC(N)=NC(N)=NCCCCCCN=C(N)N=C(N)NC1=CC=C(Cl)C=C1 GHXZTYHSJHQHIJ-UHFFFAOYSA-N 0.000 description 7
239000000043 antiallergic agent Substances 0.000 description 7
229960003260 chlorhexidine Drugs 0.000 description 7
238000004132 cross linking Methods 0.000 description 7
239000000551 dentifrice Substances 0.000 description 7
230000003993 interaction Effects 0.000 description 7
229940068918 polyethylene glycol 400 Drugs 0.000 description 7
150000003839 salts Chemical class 0.000 description 7
230000002459 sustained effect Effects 0.000 description 7
238000012360 testing method Methods 0.000 description 7
241000233866 Fungi Species 0.000 description 6
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 6
MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 6
TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 6
240000005428 Pistacia lentiscus Species 0.000 description 6
238000013270 controlled release Methods 0.000 description 6
238000004090 dissolution Methods 0.000 description 6
239000003102 growth factor Substances 0.000 description 6
230000007246 mechanism Effects 0.000 description 6
235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 6
229920000053 polysorbate 80 Polymers 0.000 description 6
239000002904 solvent Substances 0.000 description 6
239000000126 substance Substances 0.000 description 6
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 5
102100035695 Gamma-aminobutyric acid receptor-associated protein Human genes 0.000 description 5
101001001372 Homo sapiens Gamma-aminobutyric acid receptor-associated protein Proteins 0.000 description 5
BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 description 5
229920000175 Pistacia lentiscus Polymers 0.000 description 5
240000004808 Saccharomyces cerevisiae Species 0.000 description 5
206010042496 Sunburn Diseases 0.000 description 5
230000009471 action Effects 0.000 description 5
239000002246 antineoplastic agent Substances 0.000 description 5
208000002399 aphthous stomatitis Diseases 0.000 description 5
229960005069 calcium Drugs 0.000 description 5
239000011575 calcium Substances 0.000 description 5
229910052791 calcium Inorganic materials 0.000 description 5
230000001684 chronic effect Effects 0.000 description 5
210000004268 dentin Anatomy 0.000 description 5
230000002538 fungal effect Effects 0.000 description 5
229920001477 hydrophilic polymer Polymers 0.000 description 5
230000002209 hydrophobic effect Effects 0.000 description 5
229960005337 lysine hydrochloride Drugs 0.000 description 5
210000004400 mucous membrane Anatomy 0.000 description 5
239000008363 phosphate buffer Substances 0.000 description 5
238000011084 recovery Methods 0.000 description 5
210000003296 saliva Anatomy 0.000 description 5
241000894007 species Species 0.000 description 5
238000010186 staining Methods 0.000 description 5
229940047908 strontium chloride hexahydrate Drugs 0.000 description 5
AMGRXJSJSONEEG-UHFFFAOYSA-L strontium dichloride hexahydrate Chemical compound O.O.O.O.O.O.Cl[Sr]Cl AMGRXJSJSONEEG-UHFFFAOYSA-L 0.000 description 5
239000000606 toothpaste Substances 0.000 description 5
229940034610 toothpaste Drugs 0.000 description 5
241000894006 Bacteria Species 0.000 description 4
208000035143 Bacterial infection Diseases 0.000 description 4
241000282412 Homo Species 0.000 description 4
206010048685 Oral infection Diseases 0.000 description 4
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 4
208000014151 Stomatognathic disease Diseases 0.000 description 4
208000036142 Viral infection Diseases 0.000 description 4
238000010521 absorption reaction Methods 0.000 description 4
239000011149 active material Substances 0.000 description 4
230000000996 additive effect Effects 0.000 description 4
230000000843 anti-fungal effect Effects 0.000 description 4
239000007864 aqueous solution Substances 0.000 description 4
235000009697 arginine Nutrition 0.000 description 4
208000022362 bacterial infectious disease Diseases 0.000 description 4
235000019658 bitter taste Nutrition 0.000 description 4
210000000988 bone and bone Anatomy 0.000 description 4
230000008468 bone growth Effects 0.000 description 4
230000001680 brushing effect Effects 0.000 description 4
238000011088 calibration curve Methods 0.000 description 4
150000001875 compounds Chemical class 0.000 description 4
239000002552 dosage form Substances 0.000 description 4
239000007937 lozenge Substances 0.000 description 4
239000013521 mastic Substances 0.000 description 4
239000006072 paste Substances 0.000 description 4
235000010603 pastilles Nutrition 0.000 description 4
230000003239 periodontal effect Effects 0.000 description 4
230000007406 plaque accumulation Effects 0.000 description 4
239000011591 potassium Substances 0.000 description 4
229960003975 potassium Drugs 0.000 description 4
YGSDEFSMJLZEOE-UHFFFAOYSA-N salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 4
VWDWKYIASSYTQR-UHFFFAOYSA-N sodium nitrate Chemical compound [Na+].[O-][N+]([O-])=O VWDWKYIASSYTQR-UHFFFAOYSA-N 0.000 description 4
239000007921 spray Substances 0.000 description 4
208000024891 symptom Diseases 0.000 description 4
230000009885 systemic effect Effects 0.000 description 4
230000001225 therapeutic effect Effects 0.000 description 4
230000009385 viral infection Effects 0.000 description 4
229920003136 Eudragit® L polymer Polymers 0.000 description 3
229920003137 Eudragit® S polymer Polymers 0.000 description 3
206010021531 Impetigo Diseases 0.000 description 3
206010061218 Inflammation Diseases 0.000 description 3
208000006877 Insect Bites and Stings Diseases 0.000 description 3
206010028080 Mucocutaneous candidiasis Diseases 0.000 description 3
DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
239000004809 Teflon Substances 0.000 description 3
229920006362 Teflon® Polymers 0.000 description 3
208000002474 Tinea Diseases 0.000 description 3
241000287411 Turdidae Species 0.000 description 3
238000005299 abrasion Methods 0.000 description 3
239000002260 anti-inflammatory agent Substances 0.000 description 3
229940121363 anti-inflammatory agent Drugs 0.000 description 3
230000001857 anti-mycotic effect Effects 0.000 description 3
229940088710 antibiotic agent Drugs 0.000 description 3
239000002543 antimycotic Substances 0.000 description 3
CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 3
229960002713 calcium chloride Drugs 0.000 description 3
125000002091 cationic group Chemical group 0.000 description 3
230000008859 change Effects 0.000 description 3
208000007287 cheilitis Diseases 0.000 description 3
238000006243 chemical reaction Methods 0.000 description 3
238000004140 cleaning Methods 0.000 description 3
238000000576 coating method Methods 0.000 description 3
239000002537 cosmetic Substances 0.000 description 3
229940124378 dental agent Drugs 0.000 description 3
229940000033 dermatological agent Drugs 0.000 description 3
239000003241 dermatological agent Substances 0.000 description 3
238000011161 development Methods 0.000 description 3
230000018109 developmental process Effects 0.000 description 3
230000003292 diminished effect Effects 0.000 description 3
230000008034 disappearance Effects 0.000 description 3
230000002708 enhancing effect Effects 0.000 description 3
235000013305 food Nutrition 0.000 description 3
239000000499 gel Substances 0.000 description 3
208000007565 gingivitis Diseases 0.000 description 3
229960002163 hydrogen peroxide Drugs 0.000 description 3
238000001727 in vivo Methods 0.000 description 3
230000004054 inflammatory process Effects 0.000 description 3
229910001629 magnesium chloride Inorganic materials 0.000 description 3
238000004519 manufacturing process Methods 0.000 description 3
239000000463 material Substances 0.000 description 3
210000002200 mouth mucosa Anatomy 0.000 description 3
RARSHUDCJQSEFJ-UHFFFAOYSA-N p-Hydroxypropiophenone Chemical compound CCC(=O)C1=CC=C(O)C=C1 RARSHUDCJQSEFJ-UHFFFAOYSA-N 0.000 description 3
210000003800 pharynx Anatomy 0.000 description 3
235000013550 pizza Nutrition 0.000 description 3
230000007505 plaque formation Effects 0.000 description 3
229920006254 polymer film Polymers 0.000 description 3
229920000193 polymethacrylate Polymers 0.000 description 3
229910052700 potassium Inorganic materials 0.000 description 3
239000002244 precipitate Substances 0.000 description 3
239000008213 purified water Substances 0.000 description 3
230000002829 reductive effect Effects 0.000 description 3
ILJOYZVVZZFIKA-UHFFFAOYSA-M sodium;1,1-dioxo-1,2-benzothiazol-3-olate;hydrate Chemical compound O.[Na+].C1=CC=C2C(=O)[N-]S(=O)(=O)C2=C1 ILJOYZVVZZFIKA-UHFFFAOYSA-M 0.000 description 3
238000003756 stirring Methods 0.000 description 3
229910001427 strontium ion Inorganic materials 0.000 description 3
235000019640 taste Nutrition 0.000 description 3
230000008467 tissue growth Effects 0.000 description 3
231100000331 toxic Toxicity 0.000 description 3
230000002588 toxic effect Effects 0.000 description 3
AQLJVWUFPCUVLO-UHFFFAOYSA-N urea hydrogen peroxide Chemical compound OO.NC(N)=O AQLJVWUFPCUVLO-UHFFFAOYSA-N 0.000 description 3
239000003981 vehicle Substances 0.000 description 3
230000002087 whitening effect Effects 0.000 description 3
DSSYKIVIOFKYAU-XCBNKYQSSA-N (R)-camphor Chemical compound C1C[C@@]2(C)C(=O)C[C@@H]1C2(C)C DSSYKIVIOFKYAU-XCBNKYQSSA-N 0.000 description 2
ALYNCZNDIQEVRV-UHFFFAOYSA-N 4-aminobenzoic acid Chemical compound NC1=CC=C(C(O)=O)C=C1 ALYNCZNDIQEVRV-UHFFFAOYSA-N 0.000 description 2
208000030507 AIDS Diseases 0.000 description 2
208000002874 Acne Vulgaris Diseases 0.000 description 2
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 description 2
WPYMKLBDIGXBTP-UHFFFAOYSA-N Benzoic acid Natural products OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
WWZKQHOCKIZLMA-UHFFFAOYSA-N Caprylic acid Natural products CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 description 2
201000006082 Chickenpox Diseases 0.000 description 2
241000723346 Cinnamomum camphora Species 0.000 description 2
208000034656 Contusions Diseases 0.000 description 2
FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
208000018035 Dental disease Diseases 0.000 description 2
201000004624 Dermatitis Diseases 0.000 description 2
206010012442 Dermatitis contact Diseases 0.000 description 2
206010012455 Dermatitis exfoliative Diseases 0.000 description 2
KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
206010015218 Erythema multiforme Diseases 0.000 description 2
ULGZDMOVFRHVEP-RWJQBGPGSA-N Erythromycin Chemical compound O([C@@H]1[C@@H](C)C(=O)O[C@@H]([C@@]([C@H](O)[C@@H](C)C(=O)[C@H](C)C[C@@](C)(O)[C@H](O[C@H]2[C@@H]([C@H](C[C@@H](C)O2)N(C)C)O)[C@H]1C)(C)O)CC)[C@H]1C[C@@](C)(OC)[C@@H](O)[C@H](C)O1 ULGZDMOVFRHVEP-RWJQBGPGSA-N 0.000 description 2
208000010201 Exanthema Diseases 0.000 description 2
WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
208000009889 Herpes Simplex Diseases 0.000 description 2
208000007514 Herpes zoster Diseases 0.000 description 2
206010061598 Immunodeficiency Diseases 0.000 description 2
208000029462 Immunodeficiency disease Diseases 0.000 description 2
WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 2
208000016604 Lyme disease Diseases 0.000 description 2
206010025421 Macule Diseases 0.000 description 2
208000025157 Oral disease Diseases 0.000 description 2
206010061324 Oral fungal infection Diseases 0.000 description 2
206010033733 Papule Diseases 0.000 description 2
208000005888 Periodontal Pocket Diseases 0.000 description 2
201000007100 Pharyngitis Diseases 0.000 description 2
201000004681 Psoriasis Diseases 0.000 description 2
206010037549 Purpura Diseases 0.000 description 2
241001672981 Purpura Species 0.000 description 2
206010037888 Rash pustular Diseases 0.000 description 2
208000035415 Reinfection Diseases 0.000 description 2
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
208000007712 Tinea Versicolor Diseases 0.000 description 2
206010056131 Tinea versicolour Diseases 0.000 description 2
208000008312 Tooth Loss Diseases 0.000 description 2
241000159241 Toxicodendron Species 0.000 description 2
241000159243 Toxicodendron radicans Species 0.000 description 2
241000893966 Trichophyton verrucosum Species 0.000 description 2
208000024780 Urticaria Diseases 0.000 description 2
206010046980 Varicella Diseases 0.000 description 2
208000000260 Warts Diseases 0.000 description 2
XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
206010000269 abscess Diseases 0.000 description 2
230000035508 accumulation Effects 0.000 description 2
238000009825 accumulation Methods 0.000 description 2
206010000496 acne Diseases 0.000 description 2
230000001154 acute effect Effects 0.000 description 2
239000000853 adhesive Substances 0.000 description 2
230000001070 adhesive effect Effects 0.000 description 2
208000002029 allergic contact dermatitis Diseases 0.000 description 2
VBIXEXWLHSRNKB-UHFFFAOYSA-N ammonium oxalate Chemical compound [NH4+].[NH4+].[O-]C(=O)C([O-])=O VBIXEXWLHSRNKB-UHFFFAOYSA-N 0.000 description 2
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 description 2
229960003942 amphotericin b Drugs 0.000 description 2
238000004458 analytical method Methods 0.000 description 2
230000000259 anti-tumor effect Effects 0.000 description 2
230000000840 anti-viral effect Effects 0.000 description 2
230000001153 anti-wrinkle effect Effects 0.000 description 2
239000004599 antimicrobial Substances 0.000 description 2
229940027983 antiseptic and disinfectant quaternary ammonium compound Drugs 0.000 description 2
238000013459 approach Methods 0.000 description 2
208000010668 atopic eczema Diseases 0.000 description 2
239000003659 bee venom Substances 0.000 description 2
230000008901 benefit Effects 0.000 description 2
230000015572 biosynthetic process Effects 0.000 description 2
239000007844 bleaching agent Substances 0.000 description 2
LLSDKQJKOVVTOJ-UHFFFAOYSA-L calcium chloride dihydrate Chemical compound O.O.[Cl-].[Cl-].[Ca+2] LLSDKQJKOVVTOJ-UHFFFAOYSA-L 0.000 description 2
229940052299 calcium chloride dihydrate Drugs 0.000 description 2
229960000846 camphor Drugs 0.000 description 2
229930008380 camphor Natural products 0.000 description 2
239000004075 cariostatic agent Substances 0.000 description 2
229960003333 chlorhexidine gluconate Drugs 0.000 description 2
YZIYKJHYYHPJIB-UUPCJSQJSA-N chlorhexidine gluconate Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O.C1=CC(Cl)=CC=C1NC(=N)NC(=N)NCCCCCCNC(=N)NC(=N)NC1=CC=C(Cl)C=C1 YZIYKJHYYHPJIB-UUPCJSQJSA-N 0.000 description 2
239000011248 coating agent Substances 0.000 description 2
208000005035 cutaneous candidiasis Diseases 0.000 description 2
230000002354 daily effect Effects 0.000 description 2
230000003247 decreasing effect Effects 0.000 description 2
229920006237 degradable polymer Polymers 0.000 description 2
210000003298 dental enamel Anatomy 0.000 description 2
239000000645 desinfectant Substances 0.000 description 2
239000003599 detergent Substances 0.000 description 2
238000009792 diffusion process Methods 0.000 description 2
208000035475 disorder Diseases 0.000 description 2
201000005884 exanthem Diseases 0.000 description 2
208000004526 exfoliative dermatitis Diseases 0.000 description 2
230000001747 exhibiting effect Effects 0.000 description 2
238000000605 extraction Methods 0.000 description 2
239000000796 flavoring agent Substances 0.000 description 2
XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 description 2
229960004413 flucytosine Drugs 0.000 description 2
235000013922 glutamic acid Nutrition 0.000 description 2
239000004220 glutamic acid Substances 0.000 description 2
230000012010 growth Effects 0.000 description 2
230000009036 growth inhibition Effects 0.000 description 2
239000003906 humectant Substances 0.000 description 2
229910052588 hydroxylapatite Inorganic materials 0.000 description 2
230000007813 immunodeficiency Effects 0.000 description 2
230000033001 locomotion Effects 0.000 description 2
210000004379 membrane Anatomy 0.000 description 2
239000012528 membrane Substances 0.000 description 2
229910052751 metal Inorganic materials 0.000 description 2
239000002184 metal Substances 0.000 description 2
230000003020 moisturizing effect Effects 0.000 description 2
208000008588 molluscum contagiosum Diseases 0.000 description 2
229940051866 mouthwash Drugs 0.000 description 2
210000004877 mucosa Anatomy 0.000 description 2
210000001640 nerve ending Anatomy 0.000 description 2
230000001706 oxygenating effect Effects 0.000 description 2
FJKROLUGYXJWQN-UHFFFAOYSA-N papa-hydroxy-benzoic acid Natural products OC(=O)C1=CC=C(O)C=C1 FJKROLUGYXJWQN-UHFFFAOYSA-N 0.000 description 2
244000052769 pathogen Species 0.000 description 2
230000001717 pathogenic effect Effects 0.000 description 2
XYJRXVWERLGGKC-UHFFFAOYSA-D pentacalcium;hydroxide;triphosphate Chemical compound [OH-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O XYJRXVWERLGGKC-UHFFFAOYSA-D 0.000 description 2
230000008569 process Effects 0.000 description 2
208000029561 pustule Diseases 0.000 description 2
150000003856 quaternary ammonium compounds Chemical class 0.000 description 2
206010037844 rash Diseases 0.000 description 2
GHMLBKRAJCXXBS-UHFFFAOYSA-N resorcinol Chemical compound OC1=CC=CC(O)=C1 GHMLBKRAJCXXBS-UHFFFAOYSA-N 0.000 description 2
201000005404 rubella Diseases 0.000 description 2
229960004889 salicylic acid Drugs 0.000 description 2
235000019613 sensory perceptions of taste Nutrition 0.000 description 2
SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
201000010153 skin papilloma Diseases 0.000 description 2
239000004317 sodium nitrate Substances 0.000 description 2
235000010344 sodium nitrate Nutrition 0.000 description 2
239000000600 sorbitol Substances 0.000 description 2
230000000638 stimulation Effects 0.000 description 2
UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
208000011580 syndromic disease Diseases 0.000 description 2
238000007910 systemic administration Methods 0.000 description 2
230000035923 taste sensation Effects 0.000 description 2
210000004357 third molar Anatomy 0.000 description 2
210000001215 vagina Anatomy 0.000 description 2
239000002966 varnish Substances 0.000 description 2
238000005303 weighing Methods 0.000 description 2
PFTAWBLQPZVEMU-DZGCQCFKSA-N (+)-catechin Chemical compound C1([C@H]2OC3=CC(O)=CC(O)=C3C[C@@H]2O)=CC=C(O)C(O)=C1 PFTAWBLQPZVEMU-DZGCQCFKSA-N 0.000 description 1
XMAYWYJOQHXEEK-OZXSUGGESA-N (2R,4S)-ketoconazole Chemical compound C1CN(C(=O)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2C=NC=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 XMAYWYJOQHXEEK-OZXSUGGESA-N 0.000 description 1
BLSQLHNBWJLIBQ-OZXSUGGESA-N (2R,4S)-terconazole Chemical compound C1CN(C(C)C)CCN1C(C=C1)=CC=C1OC[C@@H]1O[C@@](CN2N=CN=C2)(C=2C(=CC(Cl)=CC=2)Cl)OC1 BLSQLHNBWJLIBQ-OZXSUGGESA-N 0.000 description 1
MPIPASJGOJYODL-SFHVURJKSA-N (R)-isoconazole Chemical compound ClC1=CC(Cl)=CC=C1[C@@H](OCC=1C(=CC=CC=1Cl)Cl)CN1C=NC=C1 MPIPASJGOJYODL-SFHVURJKSA-N 0.000 description 1
MCCACAIVAXEFAL-UHFFFAOYSA-N 1-[2-(2,4-dichlorophenyl)-2-[(2,4-dichlorophenyl)methoxy]ethyl]imidazole;nitric acid Chemical compound O[N+]([O-])=O.ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 MCCACAIVAXEFAL-UHFFFAOYSA-N 0.000 description 1
OCAPBUJLXMYKEJ-UHFFFAOYSA-N 1-[biphenyl-4-yl(phenyl)methyl]imidazole Chemical compound C1=NC=CN1C(C=1C=CC(=CC=1)C=1C=CC=CC=1)C1=CC=CC=C1 OCAPBUJLXMYKEJ-UHFFFAOYSA-N 0.000 description 1
LEZWWPYKPKIXLL-UHFFFAOYSA-N 1-{2-(4-chlorobenzyloxy)-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound C1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 LEZWWPYKPKIXLL-UHFFFAOYSA-N 0.000 description 1
QXHHHPZILQDDPS-UHFFFAOYSA-N 1-{2-[(2-chloro-3-thienyl)methoxy]-2-(2,4-dichlorophenyl)ethyl}imidazole Chemical compound S1C=CC(COC(CN2C=NC=C2)C=2C(=CC(Cl)=CC=2)Cl)=C1Cl QXHHHPZILQDDPS-UHFFFAOYSA-N 0.000 description 1
VHVPQPYKVGDNFY-DFMJLFEVSA-N 2-[(2r)-butan-2-yl]-4-[4-[4-[4-[[(2r,4s)-2-(2,4-dichlorophenyl)-2-(1,2,4-triazol-1-ylmethyl)-1,3-dioxolan-4-yl]methoxy]phenyl]piperazin-1-yl]phenyl]-1,2,4-triazol-3-one Chemical compound O=C1N([C@H](C)CC)N=CN1C1=CC=C(N2CCN(CC2)C=2C=CC(OC[C@@H]3O[C@](CN4N=CN=C4)(OC3)C=3C(=CC(Cl)=CC=3)Cl)=CC=2)C=C1 VHVPQPYKVGDNFY-DFMJLFEVSA-N 0.000 description 1
JYJDKUOZAHYHLX-UHFFFAOYSA-N 2-amino-3-(2-phenylethenyl)phenol Chemical compound NC1=C(O)C=CC=C1C=CC1=CC=CC=C1 JYJDKUOZAHYHLX-UHFFFAOYSA-N 0.000 description 1
MBRHNTMUYWQHMR-UHFFFAOYSA-N 2-aminoethanol;6-cyclohexyl-1-hydroxy-4-methylpyridin-2-one Chemical compound NCCO.ON1C(=O)C=C(C)C=C1C1CCCCC1 MBRHNTMUYWQHMR-UHFFFAOYSA-N 0.000 description 1
WFJIVOKAWHGMBH-UHFFFAOYSA-N 4-hexylbenzene-1,3-diol Chemical compound CCCCCCC1=CC=C(O)C=C1O WFJIVOKAWHGMBH-UHFFFAOYSA-N 0.000 description 1
ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
FTGPOQQGJVJDCT-UHFFFAOYSA-N 9-aminoacridine hydrochloride Chemical compound Cl.C1=CC=C2C(N)=C(C=CC=C3)C3=NC2=C1 FTGPOQQGJVJDCT-UHFFFAOYSA-N 0.000 description 1
241000235389 Absidia Species 0.000 description 1
244000235603 Acacia catechu Species 0.000 description 1
201000000674 African histoplasmosis Diseases 0.000 description 1
244000144725 Amygdalus communis Species 0.000 description 1
235000011437 Amygdalus communis Nutrition 0.000 description 1
235000006226 Areca catechu Nutrition 0.000 description 1
201000002909 Aspergillosis Diseases 0.000 description 1
208000036641 Aspergillus infections Diseases 0.000 description 1
241000235579 Basidiobolus Species 0.000 description 1
239000004342 Benzoyl peroxide Substances 0.000 description 1
OMPJBNCRMGITSC-UHFFFAOYSA-N Benzoylperoxide Chemical compound C=1C=CC=CC=1C(=O)OOC(=O)C1=CC=CC=C1 OMPJBNCRMGITSC-UHFFFAOYSA-N 0.000 description 1
241000228405 Blastomyces dermatitidis Species 0.000 description 1
206010005098 Blastomycosis Diseases 0.000 description 1
206010006326 Breath odour Diseases 0.000 description 1
108090000312 Calcium Channels Proteins 0.000 description 1
102000003922 Calcium Channels Human genes 0.000 description 1
241000222173 Candida parapsilosis Species 0.000 description 1
241000282472 Canis lupus familiaris Species 0.000 description 1
BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 description 1
108091006146 Channels Proteins 0.000 description 1
241000498849 Chlamydiales Species 0.000 description 1
ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
206010008803 Chromoblastomycosis Diseases 0.000 description 1
208000015116 Chromomycosis Diseases 0.000 description 1
208000008818 Chronic Mucocutaneous Candidiasis Diseases 0.000 description 1
241000222290 Cladosporium Species 0.000 description 1
QCDFBFJGMNKBDO-UHFFFAOYSA-N Clioquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(Cl)C2=C1 QCDFBFJGMNKBDO-UHFFFAOYSA-N 0.000 description 1
241000223205 Coccidioides immitis Species 0.000 description 1
206010011409 Cross infection Diseases 0.000 description 1
201000007336 Cryptococcosis Diseases 0.000 description 1
241000221204 Cryptococcus neoformans Species 0.000 description 1
FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
IIUZTXTZRGLYTI-UHFFFAOYSA-N Dihydrogriseofulvin Natural products COC1CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 IIUZTXTZRGLYTI-UHFFFAOYSA-N 0.000 description 1
101100536354 Drosophila melanogaster tant gene Proteins 0.000 description 1
206010013911 Dysgeusia Diseases 0.000 description 1
208000017701 Endocrine disease Diseases 0.000 description 1
229920003151 Eudragit® RL polymer Polymers 0.000 description 1
229920003166 Eudragit® RL/RS polymer Polymers 0.000 description 1
241000282326 Felis catus Species 0.000 description 1
206010070840 Gastrointestinal tract irritation Diseases 0.000 description 1
108010010803 Gelatin Proteins 0.000 description 1
229930182566 Gentamicin Natural products 0.000 description 1
CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 1
201000003950 Geotrichosis Diseases 0.000 description 1
244000168141 Geotrichum candidum Species 0.000 description 1
235000017388 Geotrichum candidum Nutrition 0.000 description 1
206010052359 Gingival abscess Diseases 0.000 description 1
208000005232 Glossitis Diseases 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
206010018612 Gonorrhoea Diseases 0.000 description 1
206010018691 Granuloma Diseases 0.000 description 1
UXWOXTQWVMFRSE-UHFFFAOYSA-N Griseoviridin Natural products O=C1OC(C)CC=C(C(NCC=CC=CC(O)CC(O)C2)=O)SCC1NC(=O)C1=COC2=N1 UXWOXTQWVMFRSE-UHFFFAOYSA-N 0.000 description 1
208000032139 Halitosis Diseases 0.000 description 1
CTETYYAZBPJBHE-UHFFFAOYSA-N Haloprogin Chemical compound ClC1=CC(Cl)=C(OCC#CI)C=C1Cl CTETYYAZBPJBHE-UHFFFAOYSA-N 0.000 description 1
206010019973 Herpes virus infection Diseases 0.000 description 1
241000228404 Histoplasma capsulatum Species 0.000 description 1
241001354006 Histoplasma capsulatum var. duboisii Species 0.000 description 1
201000002563 Histoplasmosis Diseases 0.000 description 1
101000627861 Homo sapiens Matrix metalloproteinase-28 Proteins 0.000 description 1
XQFRJNBWHJMXHO-RRKCRQDMSA-N IDUR Chemical compound C1[C@H](O)[C@@H](CO)O[C@H]1N1C(=O)NC(=O)C(I)=C1 XQFRJNBWHJMXHO-RRKCRQDMSA-N 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
102000014150 Interferons Human genes 0.000 description 1
108010050904 Interferons Proteins 0.000 description 1
108090000862 Ion Channels Proteins 0.000 description 1
102000004310 Ion Channels Human genes 0.000 description 1
244000285963 Kluyveromyces fragilis Species 0.000 description 1
QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 1
ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 1
229930064664 L-arginine Natural products 0.000 description 1
235000014852 L-arginine Nutrition 0.000 description 1
OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 1
201000008197 Laryngitis Diseases 0.000 description 1
WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
206010067125 Liver injury Diseases 0.000 description 1
102100026799 Matrix metalloproteinase-28 Human genes 0.000 description 1
241000235048 Meyerozyma guilliermondii Species 0.000 description 1
BYBLEWFAAKGYCD-UHFFFAOYSA-N Miconazole Chemical compound ClC1=CC(Cl)=CC=C1COC(C=1C(=CC(Cl)=CC=1)Cl)CN1C=NC=C1 BYBLEWFAAKGYCD-UHFFFAOYSA-N 0.000 description 1
241000160608 Mimus gilvus Species 0.000 description 1
241000235395 Mucor Species 0.000 description 1
DDUHZTYCFQRHIY-UHFFFAOYSA-N Negwer: 6874 Natural products COC1=CC(=O)CC(C)C11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-UHFFFAOYSA-N 0.000 description 1
229930193140 Neomycin Natural products 0.000 description 1
206010029098 Neoplasm skin Diseases 0.000 description 1
206010060860 Neurological symptom Diseases 0.000 description 1
244000061176 Nicotiana tabacum Species 0.000 description 1
235000002637 Nicotiana tabacum Nutrition 0.000 description 1
206010029803 Nosocomial infection Diseases 0.000 description 1
CANCCLAKQQHLNK-LSDHHAIUSA-N O-[[(1R,8S)-4-tricyclo[6.2.1.02,7]undeca-2(7),3,5-trienyl]] N-methyl-N-(3-methylphenyl)carbamothioate Chemical compound CN(C(=S)Oc1ccc2[C@H]3CC[C@H](C3)c2c1)c1cccc(C)c1 CANCCLAKQQHLNK-LSDHHAIUSA-N 0.000 description 1
208000001388 Opportunistic Infections Diseases 0.000 description 1
206010068319 Oropharyngeal pain Diseases 0.000 description 1
229910019142 PO4 Inorganic materials 0.000 description 1
241001537205 Paracoccidioides Species 0.000 description 1
206010033767 Paracoccidioides infections Diseases 0.000 description 1
201000000301 Paracoccidioidomycosis Diseases 0.000 description 1
241000222831 Phialophora <Chaetothyriales> Species 0.000 description 1
108010093965 Polymyxin B Proteins 0.000 description 1
NPYPAHLBTDXSSS-UHFFFAOYSA-N Potassium ion Chemical compound [K+] NPYPAHLBTDXSSS-UHFFFAOYSA-N 0.000 description 1
201000004328 Pulpitis Diseases 0.000 description 1
206010037464 Pulpitis dental Diseases 0.000 description 1
241000223667 Rhinocladiella Species 0.000 description 1
241000293824 Rhinosporidium seeberi Species 0.000 description 1
241000235527 Rhizopus Species 0.000 description 1
IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 description 1
241000235343 Saccharomycetales Species 0.000 description 1
208000000453 Skin Neoplasms Diseases 0.000 description 1
241001149962 Sporothrix Species 0.000 description 1
206010041736 Sporotrichosis Diseases 0.000 description 1
241000194019 Streptococcus mutans Species 0.000 description 1
NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
206010042938 Systemic candida Diseases 0.000 description 1
240000004460 Tanacetum coccineum Species 0.000 description 1
208000025371 Taste disease Diseases 0.000 description 1
206010043183 Teething Diseases 0.000 description 1
239000004098 Tetracycline Substances 0.000 description 1
241000906446 Theraps Species 0.000 description 1
241000223238 Trichophyton Species 0.000 description 1
241000223229 Trichophyton rubrum Species 0.000 description 1
241001480048 Trichophyton tonsurans Species 0.000 description 1
241001480050 Trichophyton violaceum Species 0.000 description 1
108010059993 Vancomycin Proteins 0.000 description 1
206010052428 Wound Diseases 0.000 description 1
208000027418 Wounds and injury Diseases 0.000 description 1
244000273928 Zingiber officinale Species 0.000 description 1
235000006886 Zingiber officinale Nutrition 0.000 description 1
ROVGZAWFACYCSP-MQBLHHJJSA-N [2-methyl-4-oxo-3-[(2z)-penta-2,4-dienyl]cyclopent-2-en-1-yl] (1r,3r)-2,2-dimethyl-3-(2-methylprop-1-enyl)cyclopropane-1-carboxylate Chemical compound CC1(C)[C@H](C=C(C)C)[C@H]1C(=O)OC1C(C)=C(C\C=C/C=C)C(=O)C1 ROVGZAWFACYCSP-MQBLHHJJSA-N 0.000 description 1
239000006096 absorbing agent Substances 0.000 description 1
DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 1
229960004150 aciclovir Drugs 0.000 description 1
MKUXAQIIEYXACX-UHFFFAOYSA-N aciclovir Chemical compound N1C(N)=NC(=O)C2=C1N(COCCO)C=N2 MKUXAQIIEYXACX-UHFFFAOYSA-N 0.000 description 1
YZODJQFXMFEJRM-UHFFFAOYSA-N acrisorcin Chemical compound CCCCCCC1=CC=C(O)C=C1O.C1=CC=C2C(N)=C(C=CC=C3)C3=NC2=C1 YZODJQFXMFEJRM-UHFFFAOYSA-N 0.000 description 1
229960004124 acrisorcin Drugs 0.000 description 1
239000004480 active ingredient Substances 0.000 description 1
239000002998 adhesive polymer Substances 0.000 description 1
235000004279 alanine Nutrition 0.000 description 1
230000001476 alcoholic effect Effects 0.000 description 1
235000010443 alginic acid Nutrition 0.000 description 1
229920000615 alginic acid Polymers 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
150000001340 alkali metals Chemical class 0.000 description 1
239000013566 allergen Substances 0.000 description 1
230000004075 alteration Effects 0.000 description 1
229940037003 alum Drugs 0.000 description 1
DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 description 1
229960003805 amantadine Drugs 0.000 description 1
229940008232 aminacrine hydrochloride Drugs 0.000 description 1
125000003277 amino group Chemical group 0.000 description 1
229940126575 aminoglycoside Drugs 0.000 description 1
230000000202 analgesic effect Effects 0.000 description 1
229940035676 analgesics Drugs 0.000 description 1
229940035674 anesthetics Drugs 0.000 description 1
201000003465 angular cheilitis Diseases 0.000 description 1
229920006318 anionic polymer Polymers 0.000 description 1
NUZWLKWWNNJHPT-UHFFFAOYSA-N anthralin Chemical compound C1C2=CC=CC(O)=C2C(=O)C2=C1C=CC=C2O NUZWLKWWNNJHPT-UHFFFAOYSA-N 0.000 description 1
230000000675 anti-caries Effects 0.000 description 1
230000003110 anti-inflammatory effect Effects 0.000 description 1
230000003260 anti-sepsis Effects 0.000 description 1
239000000427 antigen Substances 0.000 description 1
102000036639 antigens Human genes 0.000 description 1
108091007433 antigens Proteins 0.000 description 1
229940064004 antiseptic throat preparations Drugs 0.000 description 1
229960003093 antiseptics and disinfectants Drugs 0.000 description 1
210000001142 back Anatomy 0.000 description 1
244000052616 bacterial pathogen Species 0.000 description 1
239000003899 bactericide agent Substances 0.000 description 1
230000000721 bacterilogical effect Effects 0.000 description 1
239000000022 bacteriostatic agent Substances 0.000 description 1
230000006399 behavior Effects 0.000 description 1
235000019400 benzoyl peroxide Nutrition 0.000 description 1
229960003328 benzoyl peroxide Drugs 0.000 description 1
229960002206 bifonazole Drugs 0.000 description 1
238000004061 bleaching Methods 0.000 description 1
230000000903 blocking effect Effects 0.000 description 1
210000001124 body fluid Anatomy 0.000 description 1
239000010839 body fluid Substances 0.000 description 1
210000004556 brain Anatomy 0.000 description 1
238000002815 broth microdilution Methods 0.000 description 1
244000309464 bull Species 0.000 description 1
201000011510 cancer Diseases 0.000 description 1
229940095731 candida albicans Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229940078916 carbamide peroxide Drugs 0.000 description 1
239000001768 carboxy methyl cellulose Substances 0.000 description 1
125000002843 carboxylic acid group Chemical group 0.000 description 1
150000001734 carboxylic acid salts Chemical class 0.000 description 1
150000001768 cations Chemical class 0.000 description 1
235000013351 cheese Nutrition 0.000 description 1
229960005091 chloramphenicol Drugs 0.000 description 1
WIIZWVCIJKGZOK-RKDXNWHRSA-N chloramphenicol Chemical compound ClC(Cl)C(=O)N[C@H](CO)[C@H](O)C1=CC=C([N+]([O-])=O)C=C1 WIIZWVCIJKGZOK-RKDXNWHRSA-N 0.000 description 1
239000000460 chlorine Substances 0.000 description 1
229910052801 chlorine Inorganic materials 0.000 description 1
MAYPHUUCLRDEAZ-UHFFFAOYSA-N chlorine peroxide Inorganic materials ClOOCl MAYPHUUCLRDEAZ-UHFFFAOYSA-N 0.000 description 1
229960004375 ciclopirox olamine Drugs 0.000 description 1
235000015165 citric acid Nutrition 0.000 description 1
229960002227 clindamycin Drugs 0.000 description 1
KDLRVYVGXIQJDK-AWPVFWJPSA-N clindamycin Chemical compound CN1C[C@H](CCC)C[C@H]1C(=O)N[C@H]([C@H](C)Cl)[C@@H]1[C@H](O)[C@H](O)[C@@H](O)[C@@H](SC)O1 KDLRVYVGXIQJDK-AWPVFWJPSA-N 0.000 description 1
230000007012 clinical effect Effects 0.000 description 1
229960005228 clioquinol Drugs 0.000 description 1
229960004022 clotrimazole Drugs 0.000 description 1
VNFPBHJOKIVQEB-UHFFFAOYSA-N clotrimazole Chemical compound ClC1=CC=CC=C1C(N1C=NC=C1)(C=1C=CC=CC=1)C1=CC=CC=C1 VNFPBHJOKIVQEB-UHFFFAOYSA-N 0.000 description 1
201000003486 coccidioidomycosis Diseases 0.000 description 1
230000001332 colony forming effect Effects 0.000 description 1
239000003086 colorant Substances 0.000 description 1
230000001010 compromised effect Effects 0.000 description 1
235000009508 confectionery Nutrition 0.000 description 1
238000011109 contamination Methods 0.000 description 1
238000011443 conventional therapy Methods 0.000 description 1
ZXJXZNDDNMQXFV-UHFFFAOYSA-M crystal violet Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1[C+](C=1C=CC(=CC=1)N(C)C)C1=CC=C(N(C)C)C=C1 ZXJXZNDDNMQXFV-UHFFFAOYSA-M 0.000 description 1
238000002425 crystallisation Methods 0.000 description 1
230000008025 crystallization Effects 0.000 description 1
239000000824 cytostatic agent Substances 0.000 description 1
230000001085 cytostatic effect Effects 0.000 description 1
230000034994 death Effects 0.000 description 1
230000002939 deleterious effect Effects 0.000 description 1
201000002170 dentin sensitivity Diseases 0.000 description 1
230000001419 dependent effect Effects 0.000 description 1
230000008021 deposition Effects 0.000 description 1
230000036576 dermal application Effects 0.000 description 1
238000013461 design Methods 0.000 description 1
238000001514 detection method Methods 0.000 description 1
206010012601 diabetes mellitus Diseases 0.000 description 1
238000000502 dialysis Methods 0.000 description 1
229960000691 diiodohydroxyquinoline Drugs 0.000 description 1
238000010790 dilution Methods 0.000 description 1
239000012895 dilution Substances 0.000 description 1
FSBVERYRVPGNGG-UHFFFAOYSA-N dimagnesium dioxido-bis[[oxido(oxo)silyl]oxy]silane hydrate Chemical compound O.[Mg+2].[Mg+2].[O-][Si](=O)O[Si]([O-])([O-])O[Si]([O-])=O FSBVERYRVPGNGG-UHFFFAOYSA-N 0.000 description 1
XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 1
OSVXSBDYLRYLIG-UHFFFAOYSA-N dioxidochlorine(.) Chemical compound O=Cl=O OSVXSBDYLRYLIG-UHFFFAOYSA-N 0.000 description 1
238000007598 dipping method Methods 0.000 description 1
231100000676 disease causative agent Toxicity 0.000 description 1
KQSRXDXJGUJRKE-UHFFFAOYSA-L disodium;[2,7-dibromo-9-(2-carboxylatophenyl)-3-oxido-6-oxoxanthen-4-yl]mercury;hydrate Chemical compound O.[Na+].[Na+].[O-]C(=O)C1=CC=CC=C1C(C1=CC(Br)=C([O-])C([Hg])=C1O1)=C2C1=CC(=O)C(Br)=C2 KQSRXDXJGUJRKE-UHFFFAOYSA-L 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
208000019164 disseminated candidiasis Diseases 0.000 description 1
229960002311 dithranol Drugs 0.000 description 1
239000003937 drug carrier Substances 0.000 description 1
229960003913 econazole Drugs 0.000 description 1
230000003028 elevating effect Effects 0.000 description 1
239000003974 emollient agent Substances 0.000 description 1
208000030172 endocrine system disease Diseases 0.000 description 1
238000005516 engineering process Methods 0.000 description 1
239000003623 enhancer Substances 0.000 description 1
230000007515 enzymatic degradation Effects 0.000 description 1
229960003276 erythromycin Drugs 0.000 description 1
210000003238 esophagus Anatomy 0.000 description 1
238000011156 evaluation Methods 0.000 description 1
238000001704 evaporation Methods 0.000 description 1
230000008020 evaporation Effects 0.000 description 1
230000003203 everyday effect Effects 0.000 description 1
238000011049 filling Methods 0.000 description 1
235000019634 flavors Nutrition 0.000 description 1
229960004884 fluconazole Drugs 0.000 description 1
RFHAOTPXVQNOHP-UHFFFAOYSA-N fluconazole Chemical compound C1=NC=NN1CC(C=1C(=CC(F)=CC=1)F)(O)CN1C=NC=N1 RFHAOTPXVQNOHP-UHFFFAOYSA-N 0.000 description 1
239000012530 fluid Substances 0.000 description 1
229910052587 fluorapatite Inorganic materials 0.000 description 1
229940077441 fluorapatite Drugs 0.000 description 1
235000013355 food flavoring agent Nutrition 0.000 description 1
230000037406 food intake Effects 0.000 description 1
230000006870 function Effects 0.000 description 1
239000008273 gelatin Substances 0.000 description 1
229920000159 gelatin Polymers 0.000 description 1
235000019322 gelatine Nutrition 0.000 description 1
235000011852 gelatine desserts Nutrition 0.000 description 1
239000003193 general anesthetic agent Substances 0.000 description 1
229960001235 gentian violet Drugs 0.000 description 1
230000002070 germicidal effect Effects 0.000 description 1
235000008397 ginger Nutrition 0.000 description 1
201000005562 gingival recession Diseases 0.000 description 1
208000001786 gonorrhea Diseases 0.000 description 1
DDUHZTYCFQRHIY-RBHXEPJQSA-N griseofulvin Chemical compound COC1=CC(=O)C[C@@H](C)[C@@]11C(=O)C(C(OC)=CC(OC)=C2Cl)=C2O1 DDUHZTYCFQRHIY-RBHXEPJQSA-N 0.000 description 1
229960002867 griseofulvin Drugs 0.000 description 1
229960001906 haloprogin Drugs 0.000 description 1
230000005802 health problem Effects 0.000 description 1
208000013210 hematogenous Diseases 0.000 description 1
231100000234 hepatic damage Toxicity 0.000 description 1
229960003258 hexylresorcinol Drugs 0.000 description 1
238000004128 high performance liquid chromatography Methods 0.000 description 1
230000003054 hormonal effect Effects 0.000 description 1
235000003642 hunger Nutrition 0.000 description 1
229920001600 hydrophobic polymer Polymers 0.000 description 1
206010020718 hyperplasia Diseases 0.000 description 1
230000002390 hyperplastic effect Effects 0.000 description 1
229960004716 idoxuridine Drugs 0.000 description 1
210000000987 immune system Anatomy 0.000 description 1
239000007943 implant Substances 0.000 description 1
238000011065 in-situ storage Methods 0.000 description 1
238000010348 incorporation Methods 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000002757 inflammatory effect Effects 0.000 description 1
230000028709 inflammatory response Effects 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
208000014674 injury Diseases 0.000 description 1
239000002054 inoculum Substances 0.000 description 1
229940047124 interferons Drugs 0.000 description 1
PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
229960002358 iodine Drugs 0.000 description 1
229910052740 iodine Inorganic materials 0.000 description 1
239000011630 iodine Substances 0.000 description 1
229940035535 iodophors Drugs 0.000 description 1
UXZFQZANDVDGMM-UHFFFAOYSA-N iodoquinol Chemical compound C1=CN=C2C(O)=C(I)C=C(I)C2=C1 UXZFQZANDVDGMM-UHFFFAOYSA-N 0.000 description 1
238000005342 ion exchange Methods 0.000 description 1
239000002563 ionic surfactant Substances 0.000 description 1
SUMDYPCJJOFFON-UHFFFAOYSA-N isethionic acid Chemical compound OCCS(O)(=O)=O SUMDYPCJJOFFON-UHFFFAOYSA-N 0.000 description 1
229960004849 isoconazole Drugs 0.000 description 1
229960004130 itraconazole Drugs 0.000 description 1
210000001847 jaw Anatomy 0.000 description 1
229960000318 kanamycin Drugs 0.000 description 1
229930027917 kanamycin Natural products 0.000 description 1
SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
229930182823 kanamycin A Natural products 0.000 description 1
229960004125 ketoconazole Drugs 0.000 description 1
210000000867 larynx Anatomy 0.000 description 1
230000000670 limiting effect Effects 0.000 description 1
IIPYXGDZVMZOAP-UHFFFAOYSA-N lithium nitrate Inorganic materials [Li+].[O-][N+]([O-])=O IIPYXGDZVMZOAP-UHFFFAOYSA-N 0.000 description 1
230000008818 liver damage Effects 0.000 description 1
238000011068 loading method Methods 0.000 description 1
230000004807 localization Effects 0.000 description 1
230000005923 long-lasting effect Effects 0.000 description 1
239000000391 magnesium silicate Substances 0.000 description 1
229910052919 magnesium silicate Inorganic materials 0.000 description 1
235000019792 magnesium silicate Nutrition 0.000 description 1
239000003550 marker Substances 0.000 description 1
230000010534 mechanism of action Effects 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
238000002483 medication Methods 0.000 description 1
229960002782 merbromin Drugs 0.000 description 1
WRWRKDRWMURIBI-UHFFFAOYSA-M mercuric amidochloride Chemical compound N[Hg]Cl WRWRKDRWMURIBI-UHFFFAOYSA-M 0.000 description 1
229960000432 mercuric amidochloride Drugs 0.000 description 1
150000002731 mercury compounds Chemical class 0.000 description 1
235000019656 metallic taste Nutrition 0.000 description 1
229960002509 miconazole Drugs 0.000 description 1
229960005040 miconazole nitrate Drugs 0.000 description 1
230000002906 microbiologic effect Effects 0.000 description 1
239000002480 mineral oil Substances 0.000 description 1
235000010446 mineral oil Nutrition 0.000 description 1
BDRTVPCFKSUHCJ-UHFFFAOYSA-N molecular hydrogen;potassium Chemical compound [K].[H][H] BDRTVPCFKSUHCJ-UHFFFAOYSA-N 0.000 description 1
239000000178 monomer Substances 0.000 description 1
230000000877 morphologic effect Effects 0.000 description 1
239000004570 mortar (masonry) Substances 0.000 description 1
208000030194 mouth disease Diseases 0.000 description 1
229960004313 naftifine Drugs 0.000 description 1
OZGNYLLQHRPOBR-DHZHZOJOSA-N naftifine Chemical compound C=1C=CC2=CC=CC=C2C=1CN(C)C\C=C\C1=CC=CC=C1 OZGNYLLQHRPOBR-DHZHZOJOSA-N 0.000 description 1
229960003255 natamycin Drugs 0.000 description 1
239000004311 natamycin Substances 0.000 description 1
235000010298 natamycin Nutrition 0.000 description 1
NCXMLFZGDNKEPB-FFPOYIOWSA-N natamycin Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C[C@@H](C)OC(=O)/C=C/[C@H]2O[C@@H]2C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 NCXMLFZGDNKEPB-FFPOYIOWSA-N 0.000 description 1
229960004927 neomycin Drugs 0.000 description 1
210000005036 nerve Anatomy 0.000 description 1
IAIWVQXQOWNYOU-FPYGCLRLSA-N nitrofural Chemical compound NC(=O)N\N=C\C1=CC=C([N+]([O-])=O)O1 IAIWVQXQOWNYOU-FPYGCLRLSA-N 0.000 description 1
229960001907 nitrofurazone Drugs 0.000 description 1
239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 1
239000000820 nonprescription drug Substances 0.000 description 1
229960002446 octanoic acid Drugs 0.000 description 1
230000003287 optical effect Effects 0.000 description 1
230000003204 osmotic effect Effects 0.000 description 1
229960003483 oxiconazole Drugs 0.000 description 1
QRJJEGAJXVEBNE-MOHJPFBDSA-N oxiconazole Chemical compound ClC1=CC(Cl)=CC=C1CO\N=C(C=1C(=CC(Cl)=CC=1)Cl)\CN1C=NC=C1 QRJJEGAJXVEBNE-MOHJPFBDSA-N 0.000 description 1
239000007800 oxidant agent Substances 0.000 description 1
230000001590 oxidative effect Effects 0.000 description 1
210000003254 palate Anatomy 0.000 description 1
210000002741 palatine tonsil Anatomy 0.000 description 1
239000001814 pectin Substances 0.000 description 1
235000010987 pectin Nutrition 0.000 description 1
229920001277 pectin Polymers 0.000 description 1
NRNCYVBFPDDJNE-UHFFFAOYSA-N pemoline Chemical compound O1C(N)=NC(=O)C1C1=CC=CC=C1 NRNCYVBFPDDJNE-UHFFFAOYSA-N 0.000 description 1
230000035515 penetration Effects 0.000 description 1
210000003899 penis Anatomy 0.000 description 1
VSIIXMUUUJUKCM-UHFFFAOYSA-D pentacalcium;fluoride;triphosphate Chemical compound [F-].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O VSIIXMUUUJUKCM-UHFFFAOYSA-D 0.000 description 1
230000035699 permeability Effects 0.000 description 1
239000008177 pharmaceutical agent Substances 0.000 description 1
230000000144 pharmacologic effect Effects 0.000 description 1
150000002989 phenols Chemical class 0.000 description 1
NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
239000010452 phosphate Substances 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
229920003023 plastic Polymers 0.000 description 1
239000004033 plastic Substances 0.000 description 1
150000004291 polyenes Chemical class 0.000 description 1
238000006116 polymerization reaction Methods 0.000 description 1
229920000024 polymyxin B Polymers 0.000 description 1
229960005266 polymyxin b Drugs 0.000 description 1
239000011148 porous material Substances 0.000 description 1
239000011736 potassium bicarbonate Substances 0.000 description 1
235000015497 potassium bicarbonate Nutrition 0.000 description 1
229910000028 potassium bicarbonate Inorganic materials 0.000 description 1
TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 description 1
229910001414 potassium ion Inorganic materials 0.000 description 1
239000000843 powder Substances 0.000 description 1
230000003449 preventive effect Effects 0.000 description 1
239000000047 product Substances 0.000 description 1
230000001737 promoting effect Effects 0.000 description 1
230000001681 protective effect Effects 0.000 description 1
229940015367 pyrethrum Drugs 0.000 description 1
IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
230000009467 reduction Effects 0.000 description 1
230000009719 regenerative response Effects 0.000 description 1
230000008439 repair process Effects 0.000 description 1
239000013557 residual solvent Substances 0.000 description 1
239000011347 resin Substances 0.000 description 1
229920005989 resin Polymers 0.000 description 1
229960001755 resorcinol Drugs 0.000 description 1
210000002345 respiratory system Anatomy 0.000 description 1
230000004044 response Effects 0.000 description 1
230000000717 retained effect Effects 0.000 description 1
150000004492 retinoid derivatives Chemical class 0.000 description 1
229960000329 ribavirin Drugs 0.000 description 1
HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 description 1
CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
235000019204 saccharin Nutrition 0.000 description 1
229940081974 saccharin Drugs 0.000 description 1
239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
235000019643 salty taste Nutrition 0.000 description 1
210000004761 scalp Anatomy 0.000 description 1
239000008301 sensodyne Substances 0.000 description 1
229940077012 sensodyne Drugs 0.000 description 1
230000001953 sensory effect Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
229940100890 silver compound Drugs 0.000 description 1
150000003379 silver compounds Chemical class 0.000 description 1
229910001961 silver nitrate Inorganic materials 0.000 description 1
229960003600 silver sulfadiazine Drugs 0.000 description 1
UEJSSZHHYBHCEL-UHFFFAOYSA-N silver(1+) sulfadiazinate Chemical compound [Ag+].C1=CC(N)=CC=C1S(=O)(=O)[N-]C1=NC=CC=N1 UEJSSZHHYBHCEL-UHFFFAOYSA-N 0.000 description 1
201000009890 sinusitis Diseases 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 1
229920001027 sodium carboxymethylcellulose Polymers 0.000 description 1
239000011780 sodium chloride Substances 0.000 description 1
239000007905 soft elastic gelatin capsule Substances 0.000 description 1
238000005063 solubilization Methods 0.000 description 1
230000007928 solubilization Effects 0.000 description 1
230000007480 spreading Effects 0.000 description 1
238000003892 spreading Methods 0.000 description 1
239000012086 standard solution Substances 0.000 description 1
230000037351 starvation Effects 0.000 description 1
150000003431 steroids Chemical class 0.000 description 1
239000012258 stirred mixture Substances 0.000 description 1
208000003265 stomatitis Diseases 0.000 description 1
229960005322 streptomycin Drugs 0.000 description 1
239000011593 sulfur Substances 0.000 description 1
229910052717 sulfur Inorganic materials 0.000 description 1
229960005349 sulfur Drugs 0.000 description 1
239000004094 surface-active agent Substances 0.000 description 1
239000000725 suspension Substances 0.000 description 1
235000021147 sweet food Nutrition 0.000 description 1
208000006379 syphilis Diseases 0.000 description 1
229960002722 terbinafine Drugs 0.000 description 1
DOMXUEMWDBAQBQ-WEVVVXLNSA-N terbinafine Chemical compound C1=CC=C2C(CN(C\C=C\C#CC(C)(C)C)C)=CC=CC2=C1 DOMXUEMWDBAQBQ-WEVVVXLNSA-N 0.000 description 1
229960000580 terconazole Drugs 0.000 description 1
229960002180 tetracycline Drugs 0.000 description 1
229930101283 tetracycline Natural products 0.000 description 1
235000019364 tetracycline Nutrition 0.000 description 1
150000003522 tetracyclines Chemical class 0.000 description 1
RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
229960004214 tioconazole Drugs 0.000 description 1
210000003371 toe Anatomy 0.000 description 1
229960003916 tolciclate Drugs 0.000 description 1
229960004880 tolnaftate Drugs 0.000 description 1
FUSNMLFNXJSCDI-UHFFFAOYSA-N tolnaftate Chemical compound C=1C=C2C=CC=CC2=CC=1OC(=S)N(C)C1=CC=CC(C)=C1 FUSNMLFNXJSCDI-UHFFFAOYSA-N 0.000 description 1
206010044008 tonsillitis Diseases 0.000 description 1
210000001036 tooth cervix Anatomy 0.000 description 1
210000000332 tooth crown Anatomy 0.000 description 1
210000003781 tooth socket Anatomy 0.000 description 1
230000036344 tooth staining Effects 0.000 description 1
231100000419 toxicity Toxicity 0.000 description 1
230000001988 toxicity Effects 0.000 description 1
230000008733 trauma Effects 0.000 description 1
229960001082 trimethoprim Drugs 0.000 description 1
IEDVJHCEMCRBQM-UHFFFAOYSA-N trimethoprim Chemical compound COC1=C(OC)C(OC)=CC(CC=2C(=NC(N)=NC=2)N)=C1 IEDVJHCEMCRBQM-UHFFFAOYSA-N 0.000 description 1
OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 1
235000002374 tyrosine Nutrition 0.000 description 1
229960003165 vancomycin Drugs 0.000 description 1
MYPYJXKWCTUITO-UHFFFAOYSA-N vancomycin Natural products O1C(C(=C2)Cl)=CC=C2C(O)C(C(NC(C2=CC(O)=CC(O)=C2C=2C(O)=CC=C3C=2)C(O)=O)=O)NC(=O)C3NC(=O)C2NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(CC(C)C)NC)C(O)C(C=C3Cl)=CC=C3OC3=CC2=CC1=C3OC1OC(CO)C(O)C(O)C1OC1CC(C)(N)C(O)C(C)O1 MYPYJXKWCTUITO-UHFFFAOYSA-N 0.000 description 1
MYPYJXKWCTUITO-LYRMYLQWSA-O vancomycin(1+) Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=C2C=C3C=C1OC1=CC=C(C=C1Cl)[C@@H](O)[C@H](C(N[C@@H](CC(N)=O)C(=O)N[C@H]3C(=O)N[C@H]1C(=O)N[C@H](C(N[C@@H](C3=CC(O)=CC(O)=C3C=3C(O)=CC=C1C=3)C([O-])=O)=O)[C@H](O)C1=CC=C(C(=C1)Cl)O2)=O)NC(=O)[C@@H](CC(C)C)[NH2+]C)[C@H]1C[C@](C)([NH3+])[C@H](O)[C@H](C)O1 MYPYJXKWCTUITO-LYRMYLQWSA-O 0.000 description 1
230000003253 viricidal effect Effects 0.000 description 1
238000005406 washing Methods 0.000 description 1
229920003169 water-soluble polymer Polymers 0.000 description 1
150000003752 zinc compounds Chemical class 0.000 description 1
239000011787 zinc oxide Substances 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/50—Preparations specially adapted for dental root treatment
- A61K6/52—Cleaning; Disinfecting
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/60—Preparations for dentistry comprising organic or organo-metallic additives
- A61K6/65—Dyes
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K6/00—Preparations for dentistry
- A61K6/60—Preparations for dentistry comprising organic or organo-metallic additives
- A61K6/69—Medicaments
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Epidemiology (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Chemical & Material Sciences (AREA)
Oral & Maxillofacial Surgery (AREA)
Nutrition Science (AREA)
Physiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Chemical Kinetics & Catalysis (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Processes Of Treating Macromolecular Substances (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Dental Preparations (AREA)
Cosmetics (AREA)

IL9474990A 1989-06-21 1990-06-15 Sustained-release film-forming liquid acrylic polymer pharmaceutical composition IL94749A (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US07/369,223 US5330746A (en)	1988-05-03	1989-06-21	Dental varnish composition, and method of use
US43266789A	1989-11-07	1989-11-07
US07/522,117 US5160737A (en)	1988-05-03	1990-03-28	Liquid polymer composition, and method of use

Publications (1)

Publication Number	Publication Date
IL94749A true IL94749A (en)	1995-01-24

Family

ID=27408910

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
IL9474990A IL94749A (en)	1989-06-21	1990-06-15	Sustained-release film-forming liquid acrylic polymer pharmaceutical composition

Country Status (7)

Country	Link
US (1)	US5160737A (de)
EP (1)	EP0404558B1 (de)
JP (1)	JPH03128316A (de)
AT (1)	ATE222505T1 (de)
CA (1)	CA2019410C (de)
DE (1)	DE69033994T2 (de)
IL (1)	IL94749A (de)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5330746A (en) *	1988-05-03	1994-07-19	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Dental varnish composition, and method of use
US5438076A (en) *	1988-05-03	1995-08-01	Perio Products, Ltd.	Liquid polymer composition, and method of use
IL97930A (en) *	1991-04-23	1996-06-18	Perio Prod Ltd	Preparations for whitening two controlled release products that contain a super-oxygen compound
HU223343B1 (hu) *	1991-05-20	2004-06-28	Novartis Ag.	Allil-amin-származékot tartalmazó gyógyászati készítmények és eljárás azok előállítására
HU219480B (hu)	1991-05-23	2001-04-28	Novartis Ag.	Eljárás gombás körömmegbetegségek ellen helyileg alkalmazható, allil-amin-származékot tartalmazó gyógyászati készítmények előállítására
US5270031A (en) *	1991-12-20	1993-12-14	Block Drug Company Inc.	Dentinal desensitizing compositions
FR2687571A1 (fr) *	1992-02-21	1993-08-27	Kandelman Daniel	Utilisation combinee de fluorures d'etain et d'amine pour differents types de traitements dentaires.
KR950007907B1 (ko) *	1992-09-01	1995-07-21	동국제약 주식회사	치주질환 치료용 막형 국소약물송달제제
US6353061B1 (en)	1993-05-26	2002-03-05	Dentsply Gmbh	α, ω-methacrylate terminated macromonomer compounds
US5998499A (en)	1994-03-25	1999-12-07	Dentsply G.M.B.H.	Liquid crystalline (meth)acrylate compounds, composition and method
US6369164B1 (en)	1993-05-26	2002-04-09	Dentsply G.M.B.H.	Polymerizable compounds and compositions
JP3220331B2 (ja) *	1993-07-20	2001-10-22	エチコン・インコーポレーテツド	非経口投与用の吸収性液体コポリマー類
CA2128912A1 (en) *	1993-08-17	1995-02-18	Zygmunt Teodorczyk	Modified phenol-aldehyde resin and binder system
EP0657160A1 (de) *	1993-12-09	1995-06-14	Unilever N.V.	Orale Zusammensetzung zur Desensibilisierung von empfindlichem Zähnem
CA2146816A1 (en)	1994-04-22	1995-10-23	Joachim E. Klee	Process and composition for preparing a dental polymer product
AT403988B (de) *	1994-05-18	1998-07-27	Lannacher Heilmittel	Festes orales retardpräparat
US6692766B1 (en) *	1994-06-15	2004-02-17	Yissum Research Development Company Of The Hebrew University Of Jerusalem	Controlled release oral drug delivery system
JP3095960B2 (ja) *	1994-10-05	2000-10-10	触媒化成工業株式会社	抗菌剤
US5522726A (en) *	1994-10-27	1996-06-04	Hodosh; Milton	Method for anesthetizing teeth
US5607686A (en) *	1994-11-22	1997-03-04	United States Surgical Corporation	Polymeric composition
US5773031A (en) *	1996-02-27	1998-06-30	L. Perrigo Company	Acetaminophen sustained-release formulation
US5611690A (en) *	1996-04-02	1997-03-18	E. Mishan & Sons, Inc.	Method and apparatus for sprayed delivery of tooth bleaching agent
US5827503A (en) *	1996-08-08	1998-10-27	Collagenex Pharmaceuticals, Inc.	Method and composition for treating periodontitis
US6096328A (en) *	1997-06-06	2000-08-01	The Procter & Gamble Company	Delivery system for an oral care substance using a strip of material having low flexural stiffness
US6197331B1 (en)	1997-07-24	2001-03-06	Perio Products Ltd.	Pharmaceutical oral patch for controlled release of pharmaceutical agents in the oral cavity
DE19737348C2 (de)	1997-08-27	2002-07-25	Dan-Gabriel Vulpescu	Neue Clindamycin und Clotrimazol enthaltende pharmazeutische Zusammensetzung
JP4136036B2 (ja) *	1997-09-19	2008-08-20	花王株式会社	歯のコーティング剤組成物
US5945457A (en) *	1997-10-01	1999-08-31	A.V. Topchiev Institute Of Petrochemical Synthesis, Russian Academy Of Science	Process for preparing biologically compatible polymers and their use in medical devices
IL142598A0 (en) *	1998-10-23	2002-03-10	Aventis Pharma Gmbh	Preparations for topical application of substances having antiandrogenic effect
ES2248015T3 (es)	1999-03-12	2006-03-16	Pfizer Products Inc.	Composiciones orales que comprenden una sal de potasio para reducir la sensibilidad del nervio central y de la dentina.
US6228354B1 (en) *	1999-07-02	2001-05-08	Allegiance Corporation	Water resistant film-forming antimicrobial skin-preparation
ATE285220T1 (de)	1999-07-02	2005-01-15	Procter & Gamble	Zusammenstzungen enthaltend organosiloxan-harze zur freisetzung von mundpflegewirkstoffen und zur verlängerung der freisetzung
US7074392B1 (en) *	2000-03-27	2006-07-11	Taro Pharmaceutical Industries Limited	Controllled delivery system of antifungal and keratolytic agents for local treatment of fungal infections
US8257688B2 (en) *	2000-03-27	2012-09-04	Taro Pharmaceuticals Industries	Controlled delivery system of antifungal and keratolytic agents for local treatment of fungal infections of the nail and surrounding tissues
US6315987B1 (en) *	2000-05-10	2001-11-13	Isp Investments Inc.	Polymeric delivery and release systems for oral care actives
EP1311232A1 (de) *	2000-08-21	2003-05-21	Unilever N.V.	Wässrige zahnpasta, die ein mit wirkstoff vermahlenden träger enthält
US20070003508A1 (en)	2005-07-01	2007-01-04	Wooley Richard E	Methods and compositions for promoting wound healing
US20040151765A1 (en) *	2001-09-18	2004-08-05	Ritchie Branson W.	Methods and compositions for wound management
US20040208842A1 (en) *	2001-09-18	2004-10-21	Ritchie Branson W.	Antimicrobial cleansing compositions and methods of use
EP1322276B1 (de) *	2000-09-26	2006-03-29	Thomas R. Patacca	Zusammensetzung zur zahnbeschichtung
DE10114247A1 (de) *	2001-03-22	2002-10-10	Heraeus Kulzer Gmbh & Co Kg	Antibiotikum-/Antibiotika-Polymer-Kombination
EP1262172A1 (de) *	2001-05-25	2002-12-04	Italmed S.N.C. Di Galli G. & Pacini G.	Flüssige Polymerzusammensetzung zur Vorbeugung und Behandlung von Krankheiten der Mundhöhle
US7244703B2 (en)	2001-06-22	2007-07-17	Bentley Pharmaceuticals, Inc.	Pharmaceutical compositions and methods for peptide treatment
US6942875B2 (en) *	2001-07-05	2005-09-13	Closure Medical Corporation	Adhesive treatment for skin yeast infections
US6767552B2 (en)	2001-07-05	2004-07-27	Closure Medical Corporation	Adhesive treatment for oral fungal infection
US6585967B2 (en) *	2001-07-05	2003-07-01	Closure Medical Corporation	Adhesive treatment for tinea cruris
US6746667B2 (en)	2001-07-05	2004-06-08	Closure Medical Corporation	Adhesive treatment for tinea pedis
US6602496B2 (en)	2001-07-05	2003-08-05	Closure Medical Corporation	Adhesive treatment for tinea corporis
FR2827517B1 (fr) *	2001-07-23	2003-10-24	Bioalliance Pharma	Systemes therapeutiques bioadhesifs a liberation prolongee
US7476697B2 (en) *	2001-09-10	2009-01-13	Patacca Thomas R	Tooth coating composition
US6573301B1 (en) *	2002-04-23	2003-06-03	Bradley Pharmaceuticals, Inc.	Carbamide peroxide compositions for the treatment of dermatological disorders and methods for their use
DE10242476B4 (de) *	2002-09-11	2006-10-26	Heraeus Kulzer Gmbh	Antibiotikum-/Antibiotika-Polymer-Kombination
US8524200B2 (en)	2002-09-11	2013-09-03	The Procter & Gamble Company	Tooth whitening products
AU2003294520A1 (en) *	2002-12-16	2004-07-09	Chx Technologies, Inc.	Temporary, pharmacologically-inactive dental coating for the in situ protection of dental therapeutic agents from saliva and abrasion from chewing
US20040185013A1 (en) *	2003-01-30	2004-09-23	Burgio Paul A.	Dental whitening compositions and methods
US20040185009A1 (en) *	2003-03-19	2004-09-23	Dexcel Pharma Technologies Ltd.	Composition and device for treating periodontal diseases
US20040223932A1 (en) *	2003-05-05	2004-11-11	Closure Medical Corporation	Adhesive treatment for acne
US20040223946A1 (en) *	2003-05-05	2004-11-11	Closure Medical Corporation	Adhesive treatment for insect and related bites
EP1622630B1 (de) *	2003-05-07	2012-08-29	Osteologix A/S	Strontium-kombinationsbehandlung zur prophylaxe/behandlung von knorpel- und knochenzuständen
AU2004237437B2 (en) *	2003-05-07	2011-01-20	Osteologix A/S	Controlled release composition containing a strontium salt
ES2275218T3 (es)	2003-05-07	2007-06-01	Osteologix A/S	Sales de estroncio hidrosolubles para el tratamiento de afecciones de cartilagos y/o huesos.
US9554984B2 (en) *	2003-11-03	2017-01-31	Jaleva Pharmaceuticals, Llc	Oral care compositions for topical application
CN101829319A (zh)	2003-12-08	2010-09-15	Cpex药品公司	用于胰岛素治疗的药用组合物及方法
GB0400264D0 (en) *	2004-01-07	2004-02-11	Polytherics Ltd	Complexes
US20080167513A1 (en)	2004-02-26	2008-07-10	Osteologlx A/S	Strontium-Containing Compounds for Use in the Prevention or Treatment of Necrotic Bone Conditions
US20070185202A1 (en) *	2004-03-03	2007-08-09	University Of Georgia Research Foundation, Inc.	Methods and compositions for ophthalmic treatment of fungal and bacterial infections
US20060069079A1 (en) *	2004-09-27	2006-03-30	Sever Nancy E	Stable amorphous cefdinir
US20060024246A1 (en) *	2004-07-29	2006-02-02	Prithwiraj Maitra	Oral care compositions with film forming polymers
US20060068364A1 (en) *	2004-09-29	2006-03-30	Struck James T	Methods and devices for the prevention and treatment of gingival recession
US7766658B2 (en) *	2004-11-30	2010-08-03	Align Technology, Inc.	Systems and methods for intra-oral diagnosis
US20060115785A1 (en)	2004-11-30	2006-06-01	Chunhua Li	Systems and methods for intra-oral drug delivery
US20060115782A1 (en) *	2004-11-30	2006-06-01	Chunhua Li	Systems and methods for coating a dental appliance
US7947508B2 (en) *	2004-11-30	2011-05-24	Align Technology, Inc.	Systems and methods for intra-oral diagnosis
DE102005007059A1 (de)	2005-02-15	2006-08-24	Röhm GmbH & Co. KG	Teilneutralisiertes anionisches (Meth)acrylat-Copolymer
US9072672B2 (en) *	2005-06-28	2015-07-07	Colgate-Palmolive Company	Compositions and methods for altering the color of teeth
EP1947934A4 (de) *	2005-11-07	2012-04-25	Jaleva Llc	Filmbildende harze als träger zur topischen anwendung pharmakologisch aktiver mittel
US20070190013A1 (en) *	2006-02-13	2007-08-16	Yeli Zhang	Film and film-forming compositions
EP1837020A1 (de)	2006-03-24	2007-09-26	Bioalliance Pharma	Bioadhäsive Schleimhautträger zur langsamen Verabreichung von aktiven Substanzen
DE102006035549A1 (de) *	2006-07-27	2008-01-31	Evonik Röhm Gmbh	Arzneiform mit mindestens zweischichtiger Trennschicht
FR2908659B1 (fr) *	2006-11-16	2011-12-02	Univ Nantes	Vernis dentaire a liberation prolongee d'antiseptique a l'aide d'une matrice comprenant au moins un polymere methacrylique,en particulier pour patient neutropenique.
JP4832350B2 (ja) *	2007-04-02	2011-12-07	株式会社日本自動車部品総合研究所	アンテナ装置
US20090047330A1 (en) *	2007-08-17	2009-02-19	Ramesh Bangalore	Oral fast dissolving films for erectile dysfunction bioactive agents
US20090047350A1 (en) *	2007-08-17	2009-02-19	Ramesh Bangalore	Perforated water soluble polymer based edible films
US9314524B2 (en) *	2007-12-31	2016-04-19	Calla Therapeutics Llc	Topical formulations of Flucytosine
US20090181068A1 (en) *	2008-01-14	2009-07-16	Dunn Richard L	Low Viscosity Liquid Polymeric Delivery System
ITPI20080025A1 (it) *	2008-03-31	2009-10-01	Italmed S R L	Composizione ad uso odontoiatrico per il trattamento delle perimplantiti
KR101039802B1 (ko) *	2008-10-08	2011-06-09	주식회사 나이벡	치아 지각과민 방지용 조성물
US8956161B2 (en)	2008-11-04	2015-02-17	Duane C Keller	Article and method for controlling oral-originated systemic disease
US8905760B2 (en) *	2008-11-04	2014-12-09	Duane C. Keller	Methods and systems for progressively treating and controlling oral periopathogens causing systemic inflammations
TWI469795B (zh)	2009-04-01	2015-01-21	美國棕欖公司	防止過敏和促進再礦化之雙作用牙劑組成物
AR076179A1 (es)	2009-04-01	2011-05-26	Colgate Palmolive Co	Composicion dentifrica no acuosa con vidrio bioaceptable y bioactivo y metodos de uso y fabricacion de la misma
TWI395595B (zh) *	2009-04-01	2013-05-11	美國棕欖公司	用於治療牙齒敏感之口腔用組成物及其使用方法與製造
US20120100192A1 (en)	2009-07-01	2012-04-26	Dexcel Pharma Technologies Ltd.	Local therapeutic release device
EP2485713B1 (de)	2009-10-05	2018-09-26	Yissum Research Development Company of the Hebrew University of Jerusalem	Flüssige vorläuferzusammensetzungen und verwendungen davon zur ph-abhängigen behandlung mit verzögerter freisetzung von oralen erkrankungen
US20110152925A1 (en) *	2009-12-22	2011-06-23	Schorr Phillip A	Skin Preparation That Immobilizes Bacteria
WO2011103397A2 (en) *	2010-02-19	2011-08-25	The University Of South Dakota	Rechargeable long-term antifungal denture materials
JP5723001B2 (ja)	2010-06-23	2015-05-27	コルゲート・パーモリブ・カンパニーＣｏｌｇａｔｅ−ＰａｌｍｏｌｉｖｅＣｏｍｐａｎｙ	治療用口腔用組成物
CN103153267B (zh) *	2010-08-18	2015-07-22	高露洁-棕榄公司	口腔护理产品及其使用和制备方法
US8865198B2 (en)	2010-10-25	2014-10-21	Dexcel Pharma Technologies Ltd.	Method for treating a periodontal disease
JP2012097037A (ja) *	2010-11-02	2012-05-24	Kao Corp	オートインデューサー−２阻害剤、並びに歯骨炎又は齲蝕病の予防及び／又は治療剤
US8591229B2 (en)	2010-12-16	2013-11-26	Duane C. Keller	Devices and methods for creating a positive pressure environment for treatment of oral biofilms associated with periodontal disease
WO2012131669A1 (en)	2011-03-29	2012-10-04	Yissum Research Development Company Of The Hebrew University Of Jerusalem, Ltd.	Film-forming composition for a ph-dependant sustained release of the active agent
EP2710085B1 (de)	2011-05-16	2018-09-26	Avery Dennison Corporation	Klebstoff mit mikropartikeln
EP2550863A1 (de)	2011-07-27	2013-01-30	Bayer Intellectual Property GmbH	Aktivstoffhaltige Partikel auf Polyacrylat-Basis
EP2780005A1 (de) *	2011-11-17	2014-09-24	Avery Dennison Corporation	Kontrollierte freisetzung eines wirkstoffes mit ph
DE102012001979A1 (de)	2012-02-02	2013-08-08	Voco Gmbh	Härtbares Gemisch umfassend Weichmacher mit einem polyalicyclischen Strukturelement zur Anwendung bei der Herstellung dentaler Werkstoffe
DE102012001978A1 (de)	2012-02-02	2013-08-08	Voco Gmbh	Dentale Kompositmaterialien enthaltend tricyclische Weichmacher
CN104736133B (zh)	2012-10-17	2020-07-10	宝洁公司	用于递送口腔护理活性物质的条带以及施用口腔护理活性物质的方法
WO2014124232A2 (en)	2013-02-07	2014-08-14	Avery Dennison Corporation	Antimicrobial adhesives having improved properties
WO2014151355A1 (en)	2013-03-15	2014-09-25	Avery Dennison Corporation	Transparent cover dressing application system and inclusion of label strip
RU2646501C2 (ru)	2013-09-11	2018-03-05	3М Инновейтив Пропертиз Компани	Композиции для полости рта
CN105530999B (zh)	2013-09-11	2019-08-16	3M创新有限公司	口腔组合物、牙齿结构以及递送口腔组合物的方法
EP3151813B1 (de)	2014-06-05	2020-12-09	Avery Dennison Corporation	Artikel mit an der substratkontaktfläche konzentriertem wirkstoff und zugehörige verfahren
JP2016084287A (ja) *	2014-10-23	2016-05-19	株式会社アヴェデス	歯周病用フィルム状外用剤及びその使用方法
CA2936740C (en)	2014-10-31	2017-10-10	Purdue Pharma	Methods and compositions particularly for treatment of attention deficit disorder
AR100459A1 (es) *	2015-05-15	2016-10-05	Química Luar S R L	Una composición farmacéutica antiviral de uso tópico
JP2015221814A (ja) *	2015-07-10	2015-12-10	コルゲート・パーモリブ・カンパニーＣｏｌｇａｔｅ−ＰａｌｍｏｌｉｖｅＣｏｍｐａｎｙ	オーラルケア製品およびその使用法および製造法
JP7153736B2 (ja) *	2018-09-26	2022-10-14	株式会社ジーシー	歯科用組成物
US10722473B2 (en)	2018-11-19	2020-07-28	Purdue Pharma L.P.	Methods and compositions particularly for treatment of attention deficit disorder
WO2020161771A1 (ja) *	2019-02-04	2020-08-13	マルホ株式会社	皮膚用組成物
IT201900018752A1 (it)	2019-10-14	2021-04-14	Alessandro Tosetti	Composizione a base di olii essenziali ad uso odontoiatrico per il trattamento della periodontite e della mucosite perimplantare

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US2984639A (en) *	1953-12-31	1961-05-16	Crusader Chemical Co Inc	Composition comprising the reaction product of a quaternary ammonium compound and a polymer of ethylenically unsaturated monomer
DE1024209B (de) *	1956-07-27	1958-02-13	Alfred Paul Rheinlaender Dr Me	Mittel zur Herstellung von alkaliloeslichen Polyamidueberzuegen
BE758280A (fr) *	1969-10-31	1971-04-30	Dow Chemical Co	Lotions cosmetiques non graisseuses
GB1294173A (en) *	1970-06-02	1972-10-25	Ici Ltd	Coating compositions
US3846542A (en) *	1970-07-20	1974-11-05	Kulzer & Co Gmbh	Acrylic tooth-filling composition containing boric acid-releasing compound
CH564340A5 (de) *	1972-06-12	1975-07-31	Sulzer Ag
GB1446709A (en) *	1972-07-06	1976-08-18	Nat Patent Dev Corp	Tooth root canal filling composition
US3956480A (en) *	1974-07-01	1976-05-11	Colgate-Palmolive Company	Treatment of teeth
US4011309A (en) *	1975-01-20	1977-03-08	Marion Laboratories, Inc.	Dentifrice composition and method for desensitizing sensitive teeth
DE3036033A1 (de) *	1980-09-24	1982-05-06	Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V., 3400 Göttingen	Wundbehandlungsmittel in pulverform und verfahren zu seiner herstellung
US4539199A (en) *	1981-01-14	1985-09-03	Egyt Gyogyszervegyeszeti Gyar	Sustained release pharmaceutical compositions
CH655656B (de) *	1982-10-07	1986-05-15
GR80494B (en) *	1983-10-07	1985-02-04	Forsyth Dental Infirmary	Intra-pocket drug delivery devices for treatment of periodontal diseases
US4631185A (en) *	1984-03-13	1986-12-23	The Trustees Of Columbia University In The City Of New York	Method of desensitizing hypersensitive dentin employing compositions containing potassium salts
JPH0742219B2 (ja) *	1984-07-26	1995-05-10	ライオン株式会社	口腔用組成物
GB8428523D0 (en) *	1984-11-12	1984-12-19	Ici Plc	Oral hygiene composition
US4701320A (en) *	1984-11-29	1987-10-20	Lederle (Japan), Ltd.	Composition stably containing minocycline for treating periodontal diseases
US4683134A (en) *	1985-12-13	1987-07-28	Victor Palinczar	Waterproof sunscreen compositions
US4775525A (en) *	1985-12-16	1988-10-04	Ivo Pera	Oral hygiene formulation containing sodium alginate
DE3544983A1 (de) *	1985-12-19	1987-06-25	Hoechst Ag	Antimykotisch wirksamer nagellack
JPH0729915B2 (ja) *	1986-02-01	1995-04-05	帝國製薬株式会社	シ−ト状口腔内貼付剤
JPS62240620A (ja) *	1986-04-10	1987-10-21	Hidekazu Masuhara	Ｎ−メタクリロイルアミノサリチル酸を含む歯牙疼痛鎮静剤
JPH0794384B2 (ja) *	1986-09-01	1995-10-11	帝国製薬株式会社	徐放性口腔内用製剤
DE3634697A1 (de) *	1986-10-11	1988-04-21	Dentaire Ivoclar Ets	Dentalwerkstoff zur bekaempfung von karies und parodontose
CA1299319C (en) *	1986-10-23	1992-04-21	Izumi Saitoh	Acrylic copolymer and skin protective
DE3720147A1 (de) *	1987-06-16	1988-12-29	Hoechst Ag	Antimykotisch wirksamer nagellack sowie verfahren zu dessen herstellung

1990
- 1990-03-28 US US07/522,117 patent/US5160737A/en not_active Expired - Lifetime
- 1990-06-15 IL IL9474990A patent/IL94749A/en not_active IP Right Cessation
- 1990-06-20 CA CA002019410A patent/CA2019410C/en not_active Expired - Fee Related
- 1990-06-21 DE DE69033994T patent/DE69033994T2/de not_active Expired - Fee Related
- 1990-06-21 JP JP2163950A patent/JPH03128316A/ja active Pending
- 1990-06-21 AT AT90306775T patent/ATE222505T1/de not_active IP Right Cessation
- 1990-06-21 EP EP90306775A patent/EP0404558B1/de not_active Expired - Lifetime

Also Published As

Publication number	Publication date
CA2019410C (en)	2001-04-10
DE69033994T2 (de)	2003-11-06
DE69033994D1 (de)	2002-09-26
ATE222505T1 (de)	2002-09-15
AU631655B2 (en)	1992-12-03
CA2019410A1 (en)	1990-12-21
US5160737A (en)	1992-11-03
AU5766790A (en)	1991-01-17
JPH03128316A (ja)	1991-05-31
EP0404558B1 (de)	2002-08-21
EP0404558A1 (de)	1990-12-27

Legal Events

Date	Code	Title	Description
1996-10-16	KB	Patent renewed
2005-07-25	MM9K	Patent not in force due to non-payment of renewal fees

Publication	Publication Date	Title
EP0404558B1 (de)	2002-08-21	Flüssige Polymerzusammensetzung und Verfahren zu ihrer Verwendung
US5438076A (en)	1995-08-01	Liquid polymer composition, and method of use
US5330746A (en)	1994-07-19	Dental varnish composition, and method of use
EP0381446B1 (de)	1994-08-10	Oral anzuwendende antifungale Arzneizubereitungen
EP1272152B1 (de)	2012-03-07	Verwendung von Chlorhexidine zur Verhinderung von Wurzelkaries
US5139768A (en)	1992-08-18	Dental composition for hypersensitive teeth
US10843013B2 (en)	2020-11-24	Liquid precursor compositions and uses thereof for a ph-dependant sustained release treatment of oral disorders
RU2301056C2 (ru)	2007-06-20	Жидкая полимерная композиция для предотвращения и лечения заболеваний полости рта
Steinberg et al.	1999	Dental drug-delivery devices: local and sustained-release applications
EP0381445B2 (de)	1998-01-28	Dentalzusammensetzung für überempfindliche Zähne
US5213803A (en)	1993-05-25	Antiviral composition and method
US6251371B1 (en)	2001-06-26	Treatment of skin or mucosa inflammation by topical treatment with preparation containing dichlorobenzyl alcohol
RU2179454C2 (ru)	2002-02-20	Лечебно-профилактические самоклеящиеся пленки местного действия для доставки дозированных количеств фтор-ионов
US5462728A (en)	1995-10-31	Pharmaceutical compositions
Addy et al.	1989	A review: Topical drug use and delivery in the mouth
RU2852444C1 (ru)	2025-12-08	Стоматологический гель-бандаж
JP2895343B2 (ja)	1999-05-24	咬合性外傷の治療剤
JPS62223114A (ja)	1987-10-01	徐放性歯周病治療剤
CA2008772A1 (en)	1990-07-31	Oral antifungal preventative, and method of use